Skip to main content
Figure 1 | BMC Infectious Diseases

Figure 1

From: The Procalcitonin And Survival Study (PASS) – A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitoninand pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients

Figure 1

Strategy for dynamic Procalcitonin-guided treatment. According to the kinetic/elimination prophile of procalcitonin, a decrease of at least 10% pr. 24 h should be observed, when bacterial infection is under control.

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us